Close Menu
Chicago News Journal
    Facebook X (Twitter) Instagram
    • Contact us
    • About us
    • Amazon Disclaimer
    • DMCA / Copyrights Disclaimer
    • Privacy Policy
    • Terms and Conditions
    Facebook X (Twitter) Instagram YouTube TikTok
    Chicago News JournalChicago News Journal
    • Home
    • US News
    • Politics
    • Business
    • Science
    • Technology
    • LifeStyle
    • Music
    • Television
    • Film
    • Books
    • Contact
      • About us
      • Amazon Disclaimer
      • DMCA / Copyrights Disclaimer
      • Privacy Policy
      • Terms and Conditions
    Chicago News Journal
    Home»US News

    Sage Therapeutics stock plunges more than 50% after FDA decision on postpartum depression drug

    AdminBy AdminAugust 7, 2023 US News
    Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram

    In this article

    • SAGE
    • BIIB
    In this photo illustration, the Sage Therapeutics logo of a biopharmaceutical company seen on a smartphone and on a pc screen.
    Pavlo Gonchar | SOPA Images | Lightrocket | Getty Images

    Shares of Sage Therapeutics fell more than 50% on Monday after the Food and Drug Administration approved the biotech company’s oral drug zuranolone for postpartum depression, but not for major depressive disorder, a bigger potential market.

    Shares of Biogen, which jointly developed the treatment with Sage, were roughly flat.

    related investing news

    UBS upgrades this kidney treatment stock, says it could rally 30%

    CNBC Pro
    UBS upgrades this kidney treatment stock, says it could rally 30%
    Hakyung Kim
    6 hours ago

    The FDA’s approval late Friday made zuranolone the first oral treatment for postpartum depression, a common complication that affects 1 in 8 women during and after pregnancy and hinders their ability to function normally.

    The two companies also applied for approval of zuranolone for major depressive disorder, also known as clinical depression. But the FDA said they did not provide enough evidence of the drug’s effectiveness in treating the condition, which affects a much larger population of patients.

    Clinical depression affects approximately 17.3 million American adults, or about 7% of the people ages 18 and older, in a given year.

    Zuranolone had the potential for $1 billion in peak sales, compared with $250 million to $500 million for postpartum depression, Jefferies analyst Michael Yee said in a research note Sunday.

    He said clinical depression “was really the big upside driver here” for the companies, while postpartum depression is “much smaller and may not be hugely profitable.”

    Wells Fargo analyst Mohit Bansal also said the clinical depression market contributed to 85% of the firm’s future sales estimates for Zuranolone. But “there could be a silver lining as the pricing power may be higher” in postpartum depression, he wrote in a Sunday research note. 

    Sage and Biogen have not disclosed Zuranolone’s price for postpartum depression treatment.

    The FDA said additional studies might be required to support the drug’s approval for clinical depression. 

    But Yee noted that Biogen is unlikely to “quickly move forward on another late-stage study” on the drug for clinical depression since the company is focusing on saving costs and recently announced layoffs.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram

    You might also be interested in...

    Body of missing 19-year-old Marine found: Sheriff's department

    November 21, 2026

    DOJ dropping Alaska midterms Senate certification lawsuit, saying case is 'moot'

    November 20, 2026

    JPMorganChase reports cyberattack on third-party service providers

    November 19, 2026

    Musk regrets nearly $500 million midterm elections spending, says hes not MAGA

    November 19, 2026

    In historic move, House Democrats nominate Hakeem Jeffries for speaker of the House

    November 18, 2026

    Federal Reserve's Cook refuses to participate in White House hearing

    November 17, 2026
    Popular Posts

    Summer Survival Guide: Get Rid of All Types of Sweat Stains

    Are You Under Attack By Howard Bloom

    DOJ dropping Alaska midterms Senate certification lawsuit, saying case is 'moot'

    Over 314,000 older Toyota and Lexus vehicles recalled for potentially dangerous airbag issue

    John Carpenter to score Zack Snyders Escape from New York remake

    Apple may be developing its own AI agent that runs your Mac | TechCrunch

    Categories
    • Books (2,460)
    • Business (3,451)
    • Events (34)
    • Film (1,065)
    • LifeStyle (2,925)
    • Music (2,799)
    • Politics (2,356)
    • Science (1,955)
    • Technology (1,820)
    • Television (3,631)
    • US News (3,296)
    Archives
    Useful Links
    • Contact us
    • About us
    • Amazon Disclaimer
    • DMCA / Copyrights Disclaimer
    • Privacy Policy
    • Terms and Conditions
    Popular Posts
    • Dragon Age: The Veilguard Is One of EA’s Biggest Single-Player Steam LaunchesDragon Age: The Veilguard Is One of EA’s Biggest Single-Player Steam Launches
    • 8 Best Men’s Shoes That Go with Everything You Wear in 20258 Best Men’s Shoes That Go with Everything You Wear in 2025
    • Cruel Summer Season 2 Episode 7 Review: It’s The End Of The World
    • 6 New Young Adult Novels for Fans of Cassandra Clare |6 New Young Adult Novels for Fans of Cassandra Clare |
    • Trump frustrated amid warning Putin can escalate conflictTrump frustrated amid warning Putin can escalate conflict
    Archives
    Categories
    • Books
    • Business
    • Events
    • Film
    • LifeStyle
    • Music
    • Politics
    • Science
    • Technology
    • Television
    • US News
    Facebook X (Twitter) Instagram YouTube TikTok
    © 2026 Chicago News Journal. All rights reserved. All articles, images, product names, logos, and brands are property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Terms of Use and Privacy Policy.

    Type above and press Enter to search. Press Esc to cancel.